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1 NorthShore University HealthSystem, Evanston, IL, 2 Propeller Health, San Francisco, CA. RATIONALE: National Asthma Education and Prevention Program (NAEPP) guidelines focus on assessment of asthma control at office visits to adjust controller therapy. In contrast, electronic medication monitors (EMMs) enable real-time assessment of increased short-acting beta-2 adrenergic (SABA) use for timely remote intervention. We examined whether current guidelines can be applied to EMMs or whether alternative recommendations are needed. METHODS: Using EMMs, SABA use was continuously monitored in 32 participants, 25-65 years of age, with uncontrolled asthma. After 4-weeks, we categorized SABA use as non-regular (as needed for treatment of symptoms) or regular, defined as either daily regardless of symptoms or preemptively before exercise or known allergen exposure. The first week of data (run-in) was excluded. Asthma control status was determined by absolute number of days of SABA use based on NAEPP guidelines (> _3 days/week for at least one week during weeks 2-4) and by relative increase in use (> _1 day/week increase for weeks 3 or 4 from week 2). Fisher's exact test was used for analysis. RESULTS: Of 32 participants, 12.5% (4/32) were regular SABA users. Using the relative definition of asthma control, 3 of 4 regular users had well controlled asthma, while the absolute definition considered all 4 as not well controlled. In non-regular users, there was a marginal relationship between asthma control status between absolute vs. relative definitions (p 5 0.38). CONCLUSIONS: Change in SABA use may predict the need to adjust controller therapy and imminent exacerbation risk. Algorithms are needed to determine both as digital signals are integrated into clinical practice. Iva hospital, Baroda, India, 4 Gotri Medical College, Baroda, India. RATIONALE: Approximately 10% of the world's asthma sufferers live in India, and asthma is widely underdiagnosed in this country. Within a growing digital health market in India, smartphone and internet-based apps can help with asthma self-management. Few studies have reported smartphone and internet access among asthma sufferers in India, and there is a lack of data regarding patient attitudes towards patient-facing asthma self-management apps. METHODS: Our physician collaborators in several settings (private hospital, government hospital) in Gujarat (India) administered paper-based surveys to patients (adults and caregivers of children) with asthma. The survey included items such as home access to smartphones and the internet, patients' willingness to use a smartphone and/or internet-based application, attitudes towards receiving push notifications (regarding medications, air quality, environmental allergens, temperature), and attitudes towards engaging with app-based educational videos and games. The survey was administered on-site within outpatient clinical sites. RESULTS: A total number of 21 patients (12 pediatric, 9 adult patients) completed the survey. Out of 21 participants, 19 (90%) participants expressed interested in using a smartphone and/or internet-based application. Eighteen (86%) had access to a smartphone and/or the internet. 19/21 (90.5%) participants were willing to watch educational videos, and all participants were willing to receive text messages and push notifications regarding medications. Among all study participants, 20/21 (95%) believed that app-delivered information regarding environmental factors would be helpful. CONCLUSIONS: The study population is above the national average of smartphone users, and these data suggest participants' willingness towards using the smartphone and internet-based applications for self-management and asthma education. RATIONALE: Acquired angioedema with low C1-inhibitor (AAE) is a rare disorder. To ensure optimal care of patients with this condition, recurrent quality assessments are necessary. METHODS: We performed a chart review of 6 AAE patients seen from 2011-2018 at our institution. The study met IRB exclusion. A checklist of variables included documentation of monoclonal gammopathy (MG), lymphoma, on-demand therapy, long-term prophylaxis, number of yearly attacks, rituximab use, and pre-procedural/pre-dental plans. RESULTS: Patients A-C have documented MG and lymphoma. Patient D has documented MG without progression to lymphoma. Patient E has Crohn's disease although has not been diagnosed with MG or lymphoma. Patient F has documented lymphoma. All 6 patients have icatibant as a rescue medication. Over the past year, patient A had 8 attacks, patients B and C had 1 attack each, patient D had 2 attacks, and patient E had no attacks. Patient F transferred care closer to home, so this data point is lacking. Patient B is the only patient who received rituximab for angioedema and responded well. None of the patients are currently on angioedema prophylaxis. Pre-procedural prophylaxis was documented at the most recent visits only for patients A,C,D, and E. CONCLUSIONS: Overall, there was consistency with documentation and management of the care of our AAE patients. There was room for improvement with documentation of pre-procedural prophylaxis. While patient E's AAE is thought to be related to autoimmune disease, all of the patients including patient E have undergone oncologic screening, which is critical given the association between AAE and lymphoproliferative disorders.
